Capture.JPG

Benefit-Risk Assessment in Drug Regulatory Decision-Making

Under FDARA 2017, FDA committed to furthering implementation of structured benefit-risk assessment into drug review

Commitments on Enhancing Benefit-Risk Assessment

  • Continue implementation of the Benefit-Risk Framework
  • Participate in stakeholder meetings
  • Draft guidance on benefit-risk assessment
  • Revise relevant MAPPs and SOPPs
  • Conduct second evaluation of Benefit-Risk Framework

Additional Opportunities to Enhance FDA’s Benefit-Risk Assessment

  • Improving accessibility for approved products
  • Use to support Advisory Committee meetings
  • Exploring additional tools to support assessment

LEARN


Image credit: FDA

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s